Symbols / BCRX $9.81 +7.10%
BCRX Chart
About
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Drug Manufacturers - Spe | Market Cap | 2.46B |
| Enterprise Value | 2.66B | Income | 263.86M | Sales | 874.84M |
| Book/sh | -0.56 | Cash/sh | 1.09 | Dividend Yield | — |
| Payout | 0.00% | Employees | 435 | IPO | — |
| P/E | 8.11 | Forward P/E | 12.23 | PEG | — |
| P/S | 2.81 | P/B | -17.55 | P/C | — |
| EV/EBITDA | 7.59 | EV/Sales | 3.04 | Quick Ratio | 1.95 |
| Current Ratio | 2.06 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | 1.21 | EPS next Y | 0.80 | EPS Growth | — |
| Revenue Growth | 209.10% | Earnings | 2026-05-04 | ROA | 43.21% |
| ROE | — | ROIC | — | Gross Margin | 79.32% |
| Oper. Margin | 65.60% | Profit Margin | 30.16% | Shs Outstand | 250.80M |
| Shs Float | 218.18M | Short Float | 16.17% | Short Ratio | 9.36 |
| Short Interest | — | 52W High | 11.31 | 52W Low | 6.00 |
| Beta | 0.76 | Avg Volume | 4.77M | Volume | 8.99M |
| Target Price | $21.30 | Recom | Strong_buy | Prev Close | $9.16 |
| Price | $9.81 | Change | 7.10% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$21.30
Mean price target
2. Current target
$9.81
Latest analyst target
3. DCF / Fair value
$18.40
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$9.81
Low
$13.00
High
$32.00
Mean
$21.30
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-30 | main | RBC Capital | Outperform → Outperform | $13 |
| 2025-12-15 | main | HC Wainwright & Co. | Buy → Buy | $32 |
| 2025-11-05 | main | Citizens | Market Outperform → Market Outperform | $25 |
| 2025-11-04 | main | Barclays | Equal-Weight → Equal-Weight | $9 |
| 2025-11-04 | main | Needham | Buy → Buy | $18 |
| 2025-10-15 | main | Cantor Fitzgerald | Overweight → Overweight | $26 |
| 2025-10-15 | main | JMP Securities | Market Outperform → Market Outperform | $27 |
| 2025-10-15 | main | Needham | Buy → Buy | $20 |
| 2025-08-04 | main | Needham | Buy → Buy | $17 |
| 2025-07-01 | main | B of A Securities | Buy → Buy | $15 |
| 2025-06-30 | reit | RBC Capital | Outperform → Outperform | $13 |
| 2025-06-30 | main | Wedbush | Outperform → Outperform | $18 |
| 2025-06-27 | reit | Needham | Buy → Buy | $17 |
| 2025-06-25 | reit | Needham | Buy → Buy | $17 |
| 2025-05-07 | main | Barclays | Equal-Weight → Equal-Weight | $11 |
| 2025-05-06 | reit | RBC Capital | Outperform → Outperform | $13 |
| 2025-05-06 | main | JP Morgan | Overweight → Overweight | $13 |
| 2025-05-06 | reit | HC Wainwright & Co. | Buy → Buy | $30 |
| 2025-05-06 | main | Needham | Buy → Buy | $17 |
| 2025-04-29 | init | Cantor Fitzgerald | — → Overweight | $20 |
- BioCryst Pharmaceuticals, Inc. (BCRX) A Good Stock To Buy Now? - Yahoo Finance hu, 19 Mar 2026 17
- BioCryst: The Buyout Rumor Is Noise, The Franchise Is Real (NASDAQ:BCRX) - Seeking Alpha ue, 17 Mar 2026 14
- BioCryst (BCRX) CLO sells 150K shares after option exercise - Stock Titan Wed, 18 Mar 2026 20
- Is It Time To Reconsider BioCryst Pharmaceuticals (BCRX) After Recent Share Price Strength - simplywall.st Wed, 18 Mar 2026 14
- BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Up 13.8% - Here's What Happened - MarketBeat Mon, 16 Mar 2026 18
- BioCryst Pharmaceuticals jumps as investors revisit profitable 2025 results, upbeat HAE pipeline data, and potential short-covering dynamics - Quiver Quantitative Mon, 16 Mar 2026 21
- BioCryst Pharmaceuticals, Inc. (BCRX) A Good Stock To Buy Now? - Insider Monkey hu, 19 Mar 2026 17
- BioCryst Pharmaceuticals (BCRX) Surges 15% Amid Takeover Specula - GuruFocus Mon, 16 Mar 2026 16
- Takeover Buzz Sends BioCryst Stock Soaring Higher - TipRanks hu, 19 Mar 2026 18
- BioCryst (BCRX) chief legal officer Barnes sells $1.37m in shares - Investing.com Wed, 18 Mar 2026 20
- BioCryst (BCRX) stock price dips premarket as new navenibart HAE data lands; Cowen talk next - TechStock² Mon, 02 Mar 2026 08
- Form 144 resale notice lists 150,000 shares (NASDAQ: BCRX) - Stock Titan Mon, 16 Mar 2026 20
- BioCryst Pharmaceuticals (NASDAQ:BCRX) Insider Sells $1,372,500.00 in Stock - MarketBeat Wed, 18 Mar 2026 20
- BioCryst (BCRX) Soars 13% on Acquisition Buzz - Yahoo Finance ue, 17 Mar 2026 04
- Avoro Capital Advisors LLC Trims Stock Position in BioCryst Pharmaceuticals, Inc. $BCRX - MarketBeat Sat, 14 Mar 2026 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 150000 | 1372500 | — | Sale at price 9.15 per share. | BARNES ALANE P | Officer | — | 2026-03-16 00:00:00 | D |
| 1 | 150000 | 826500 | — | Conversion of Exercise of derivative security at price 5.51 per share. | BARNES ALANE P | Officer | — | 2026-03-16 00:00:00 | D |
| 2 | 305995 | 985304 | — | Conversion of Exercise of derivative security at price 3.22 per share. | STONEHOUSE JON P | Director | — | 2026-03-02 00:00:00 | D |
| 3 | 528 | 4620 | — | Stock Award(Grant) at price 8.75 per share. | MILNE JILL C. PH.D. | Director | — | 2026-02-27 00:00:00 | D |
| 4 | 642 | 5618 | — | Stock Award(Grant) at price 8.75 per share. | MCKEE AMY E | Director | — | 2026-02-27 00:00:00 | D |
| 5 | 421 | 3684 | — | Stock Award(Grant) at price 8.75 per share. | STONEHOUSE JON P | Director | — | 2026-02-27 00:00:00 | D |
| 6 | 1285 | 11244 | — | Stock Award(Grant) at price 8.75 per share. | FRANK STEVEN R | Director | — | 2026-02-27 00:00:00 | D |
| 7 | 848 | 7420 | — | Stock Award(Grant) at price 8.75 per share. | MILANO VINCENT J | Director | — | 2026-02-27 00:00:00 | D |
| 8 | 14854 | — | — | Stock Award(Grant) at price 0.00 per share. | MILNE JILL C. PH.D. | Director | — | 2026-01-23 00:00:00 | D |
| 9 | 21773 | 166563 | — | Sale at price 7.65 per share. | BARNES ALANE P | Officer | — | 2025-12-22 00:00:00 | D |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -174.84K | -134.61K | -6.31M | -416.43K |
| TaxRateForCalcs | 0.01 | 0.21 | 0.21 | 0.21 |
| NormalizedEBITDA | 365.14M | 13.45M | -86.28M | -141.87M |
| TotalUnusualItems | -17.48M | -641.00K | -30.06M | -1.98M |
| TotalUnusualItemsExcludingGoodwill | -17.48M | -641.00K | -30.06M | -1.98M |
| NetIncomeFromContinuingOperationNetMinorityInterest | 263.86M | -88.88M | -226.54M | -247.12M |
| ReconciledDepreciation | 1.39M | 1.25M | 1.66M | 1.44M |
| ReconciledCostOfRevenue | 19.07M | 12.27M | 4.66M | 6.59M |
| EBITDA | 347.65M | 12.81M | -116.33M | -143.85M |
| EBIT | 346.26M | 11.56M | -117.99M | -145.29M |
| NetInterestIncome | -68.20M | -83.77M | -92.46M | -93.97M |
| InterestExpense | 78.87M | 98.52M | 108.24M | 99.09M |
| InterestIncome | 10.67M | 14.75M | 15.78M | 5.13M |
| NormalizedIncome | 281.17M | -88.37M | -202.79M | -245.55M |
| NetIncomeFromContinuingAndDiscontinuedOperation | 263.86M | -88.88M | -226.54M | -247.12M |
| TotalExpenses | 533.85M | 453.25M | 435.12M | 419.26M |
| TotalOperatingIncomeAsReported | 340.99M | -2.54M | -103.71M | -148.44M |
| DilutedAverageShares | 218.58M | 206.70M | 192.20M | 185.91M |
| BasicAverageShares | 209.89M | 206.70M | 192.20M | 185.91M |
| DilutedEPS | 1.21 | -0.43 | -1.18 | -1.33 |
| BasicEPS | 1.26 | -0.43 | -1.18 | -1.33 |
| DilutedNIAvailtoComStockholders | 263.86M | -88.88M | -226.54M | -247.12M |
| NetIncomeCommonStockholders | 263.86M | -88.88M | -226.54M | -247.12M |
| NetIncome | 263.86M | -88.88M | -226.54M | -247.12M |
| NetIncomeIncludingNoncontrollingInterests | 263.86M | -88.88M | -226.54M | -247.12M |
| NetIncomeContinuousOperations | 263.86M | -88.88M | -226.54M | -247.12M |
| TaxProvision | 3.53M | 1.93M | 310.00K | 2.73M |
| PretaxIncome | 267.39M | -86.95M | -226.23M | -244.38M |
| OtherIncomeExpense | -5.39M | -641.00K | -30.06M | -1.98M |
| OtherNonOperatingIncomeExpenses | 12.09M | |||
| SpecialIncomeCharges | -17.33M | 0.00 | -29.02M | 0.00 |
| OtherSpecialCharges | 17.33M | 29.02M | -55.84M | |
| GainOnSaleOfSecurity | -152.00K | -641.00K | -1.04M | -1.98M |
| NetNonOperatingInterestIncomeExpense | -68.20M | -83.77M | -92.46M | -93.97M |
| InterestExpenseNonOperating | 78.87M | 98.52M | 108.24M | 99.09M |
| InterestIncomeNonOperating | 10.67M | 14.75M | 15.78M | 5.13M |
| OperatingIncome | 340.99M | -2.54M | -103.71M | -148.44M |
| OperatingExpense | 514.77M | 440.99M | 430.46M | 412.67M |
| ResearchAndDevelopment | 166.13M | 174.64M | 216.57M | 253.30M |
| SellingGeneralAndAdministration | 348.65M | 266.35M | 213.89M | 159.37M |
| GrossProfit | 855.76M | 438.44M | 326.75M | 264.23M |
| CostOfRevenue | 19.07M | 12.27M | 4.66M | 6.59M |
| TotalRevenue | 874.84M | 450.71M | 331.41M | 270.83M |
| OperatingRevenue | 874.84M | 450.71M | 331.41M | 270.83M |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 213.06M | 208.54M | 205.77M | 187.91M |
| ShareIssued | 213.06M | 208.54M | 205.77M | 187.91M |
| NetDebt | 337.50M | 691.21M | 700.62M | 428.51M |
| TotalDebt | 438.87M | 808.74M | 825.15M | 741.45M |
| TangibleBookValue | -119.15M | -475.93M | -455.53M | -294.60M |
| InvestedCapital | 308.08M | 319.99M | 355.74M | 438.68M |
| WorkingCapital | 208.28M | 261.58M | 345.98M | 410.99M |
| NetTangibleAssets | -119.15M | -475.93M | -455.53M | -294.60M |
| CapitalLeaseObligations | 11.64M | 12.82M | 13.88M | 8.17M |
| CommonStockEquity | -119.15M | -475.93M | -455.53M | -294.60M |
| TotalCapitalization | 308.08M | 319.99M | 355.74M | 438.68M |
| TotalEquityGrossMinorityInterest | -119.15M | -475.93M | -455.53M | -294.60M |
| StockholdersEquity | -119.15M | -475.93M | -455.53M | -294.60M |
| GainsLossesNotAffectingRetainedEarnings | 38.00K | 921.00K | 1.34M | 26.00K |
| OtherEquityAdjustments | 38.00K | 921.00K | 1.34M | 26.00K |
| RetainedEarnings | -1.51B | -1.77B | -1.68B | -1.45B |
| AdditionalPaidInCapital | 1.38B | 1.29B | 1.22B | 1.16B |
| CapitalStock | 2.13M | 2.08M | 2.06M | 1.88M |
| CommonStock | 2.13M | 2.08M | 2.06M | 1.88M |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 633.31M | 966.35M | 972.49M | 844.60M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 437.25M | 805.97M | 822.50M | 739.08M |
| LongTermDebtAndCapitalLeaseObligation | 437.25M | 805.97M | 822.50M | 739.08M |
| LongTermCapitalLeaseObligation | 10.01M | 10.05M | 11.23M | 5.80M |
| LongTermDebt | 427.23M | 795.92M | 811.26M | 733.28M |
| CurrentLiabilities | 196.07M | 160.38M | 149.99M | 105.51M |
| OtherCurrentLiabilities | 52.20M | 32.68M | 23.57M | |
| CurrentDeferredLiabilities | 0.00 | 1.22M | 1.42M | |
| CurrentDeferredRevenue | 0.00 | 1.22M | 1.42M | |
| CurrentDebtAndCapitalLeaseObligation | 1.63M | 2.77M | 2.65M | 2.37M |
| CurrentCapitalLeaseObligation | 1.63M | 2.77M | 2.65M | 2.37M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 50.86M | 48.63M | 36.52M | 22.12M |
| CurrentProvisions | 26.63M | 32.12M | 26.51M | 14.33M |
| PayablesAndAccruedExpenses | 64.75M | 44.19M | 60.75M | 65.46M |
| CurrentAccruedExpenses | 39.96M | 17.95M | 21.33M | 43.41M |
| Payables | 24.79M | 26.23M | 39.42M | 22.06M |
| OtherPayable | 8.96M | 14.59M | 18.52M | 7.70M |
| TotalTaxPayable | 410.00K | 2.62M | ||
| AccountsPayable | 15.83M | 11.64M | 20.89M | 14.36M |
| TotalAssets | 514.16M | 490.42M | 516.96M | 550.00M |
| TotalNonCurrentAssets | 109.81M | 68.45M | 20.99M | 33.50M |
| OtherNonCurrentAssets | 29.66M | 28.34M | 80.00K | 6.81M |
| InvestmentsAndAdvances | 61.16M | 20.32M | 0.00 | 18.08M |
| InvestmentinFinancialAssets | 6.83M | |||
| AvailableForSaleSecurities | 6.83M | |||
| NetPPE | 18.99M | 19.79M | 20.91M | 8.62M |
| AccumulatedDepreciation | -9.39M | -12.35M | -11.21M | -9.55M |
| GrossPPE | 28.38M | 32.13M | 32.12M | 18.17M |
| Leases | 10.44M | 10.36M | 10.21M | 10.14M |
| ConstructionInProgress | 0.00 | 97.00K | 0.00 | |
| OtherProperties | 15.80M | 18.23M | 18.56M | 4.59M |
| MachineryFurnitureEquipment | 2.15M | 3.44M | 3.35M | 3.44M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 404.35M | 421.97M | 495.97M | 516.50M |
| OtherCurrentAssets | 17.18M | 13.75M | 19.54M | 12.59M |
| RestrictedCash | 201.00K | 210.00K | 1.80M | 1.47M |
| PrepaidAssets | 9.99M | |||
| Inventory | 5.40M | 8.09M | 28.68M | 27.53M |
| InventoriesAdjustmentsAllowances | -775.00K | -2.65M | -1.60M | -1.18M |
| OtherInventories | -23.99M | -23.19M | ||
| FinishedGoods | 7.28M | 7.76M | 6.24M | 4.81M |
| WorkInProcess | 12.89M | 16.15M | 17.59M | 14.99M |
| RawMaterials | 10.00M | 10.01M | 6.45M | 8.91M |
| Receivables | 106.82M | 79.07M | 56.95M | 50.60M |
| AccountsReceivable | 106.82M | 79.07M | 56.95M | 50.60M |
| CashCashEquivalentsAndShortTermInvestments | 274.75M | 320.85M | 388.99M | 424.31M |
| OtherShortTermInvestments | 185.01M | 216.14M | 278.34M | 119.54M |
| CashAndCashEquivalents | 89.74M | 104.71M | 110.64M | 304.77M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | 344.90M | -53.14M | -97.31M | -163.20M |
| RepaymentOfDebt | -301.99M | -1.70M | -241.62M | 0.00 |
| IssuanceOfDebt | 0.00 | 0.00 | 300.00M | 73.07M |
| IssuanceOfCapitalStock | 59.00K | 34.00K | 342.00K | 190.00K |
| CapitalExpenditure | -2.47M | -1.12M | -2.17M | -1.35M |
| InterestPaidSupplementalData | 23.73M | 30.38M | 22.14M | 0.00 |
| IncomeTaxPaidSupplementalData | 1.60M | 1.43M | 3.54M | 118.00K |
| EndCashPosition | 91.34M | 106.32M | 112.45M | 306.24M |
| BeginningCashPosition | 106.32M | 112.45M | 306.24M | 507.73M |
| EffectOfExchangeRateChanges | 1.27M | -936.00K | 362.00K | 566.00K |
| ChangesInCash | -16.26M | -5.19M | -194.15M | -202.06M |
| FinancingCashFlow | -349.93M | -5.76M | 32.48M | 88.03M |
| CashFlowFromContinuingFinancingActivities | -349.93M | -5.76M | 32.48M | 88.03M |
| NetOtherFinancingCharges | -57.12M | -7.54M | -34.58M | 293.87M |
| ProceedsFromStockOptionExercised | 9.12M | 3.44M | 8.34M | 14.77M |
| NetCommonStockIssuance | 59.00K | 34.00K | 342.00K | 190.00K |
| CommonStockIssuance | 59.00K | 34.00K | 342.00K | 190.00K |
| NetIssuancePaymentsOfDebt | -301.99M | -1.70M | 58.38M | 73.07M |
| NetShortTermDebtIssuance | 73.07M | 0.00 | ||
| ShortTermDebtPayments | 0.00 | 0.00 | ||
| ShortTermDebtIssuance | 73.07M | 0.00 | ||
| NetLongTermDebtIssuance | -301.99M | -1.70M | 58.38M | 73.07M |
| LongTermDebtPayments | -301.99M | -1.70M | -241.62M | 0.00 |
| LongTermDebtIssuance | 0.00 | 0.00 | 300.00M | 73.07M |
| InvestingCashFlow | -13.69M | 52.59M | -131.50M | -128.24M |
| CashFlowFromContinuingInvestingActivities | -13.69M | 52.59M | -131.50M | -128.24M |
| NetOtherInvestingChanges | 550.00K | |||
| NetInvestmentPurchaseAndSale | -5.59M | 53.72M | -129.33M | -126.89M |
| SaleOfInvestment | 256.65M | 320.48M | 385.08M | 117.40M |
| PurchaseOfInvestment | -262.24M | -266.76M | -514.41M | -244.28M |
| NetBusinessPurchaseAndSale | -6.18M | 0.00 | 0.00 | |
| PurchaseOfBusiness | -6.18M | 0.00 | 0.00 | |
| NetPPEPurchaseAndSale | -2.47M | -1.12M | -2.17M | -1.35M |
| PurchaseOfPPE | -2.47M | -1.12M | -2.17M | -1.35M |
| OperatingCashFlow | 347.37M | -52.02M | -95.14M | -161.85M |
| CashFlowFromContinuingOperatingActivities | 347.37M | -52.02M | -95.14M | -161.85M |
| ChangeInWorkingCapital | -56.90M | -87.28M | -32.40M | -58.95M |
| ChangeInOtherWorkingCapital | -1.23M | -109.00K | 1.28M | |
| ChangeInOtherCurrentLiabilities | -68.43M | -77.16M | -29.34M | |
| ChangeInPayablesAndAccruedExpense | 57.80M | 14.78M | -16.81M | -22.36M |
| ChangeInAccruedExpense | 0.00 | 0.00 | 4.17M | |
| ChangeInInterestPayable | 0.00 | 0.00 | 4.17M | |
| ChangeInPayable | 57.80M | 14.78M | -16.81M | -22.36M |
| ChangeInAccountPayable | 57.80M | 14.78M | -16.81M | -22.36M |
| ChangeInPrepaidAssets | -7.83M | 1.96M | -6.82M | -2.58M |
| ChangeInInventory | -1.64M | -4.16M | -1.45M | -12.42M |
| ChangeInReceivables | -36.81M | -22.70M | -6.09M | -21.47M |
| OtherNonCashItems | 30.85M | 67.61M | 85.80M | 98.92M |
| StockBasedCompensation | 80.75M | 65.41M | 55.62M | 44.70M |
| AssetImpairmentCharge | 985.00K | 1.35M | 1.97M | 932.00K |
| AmortizationOfSecurities | -4.33M | -11.47M | -10.26M | -1.78M |
| DepreciationAmortizationDepletion | 1.39M | 1.25M | 1.66M | 1.44M |
| DepreciationAndAmortization | 1.39M | 1.25M | 1.66M | 1.44M |
| Depreciation | 1.39M | 1.25M | 1.66M | 1.44M |
| OperatingGainsLosses | 30.76M | 29.02M | -55.84M | |
| EarningsLossesFromEquityInvestments | 17.55M | 0.00 | 0.00 | |
| GainLossOnInvestmentSecurities | -550.00K | |||
| GainLossOnSaleOfBusiness | -3.57M | 0.00 | 0.00 | |
| NetIncomeFromContinuingOperations | 263.86M | -88.88M | -226.54M | -247.12M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for BCRX
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|